Onkologie. 2024:18(5):300-304 | DOI: 10.36290/xon.2024.062

Incidental finding of cervical adenocarcinoma after complication of caesarean section

František Velčický1, 2, Monika Náležinská1, 2, Jiří Nagy3, Josef Chovanec1, 2
1 Oddělení gynekologické onkologie Kliniky operační onkologie Masarykova onkologického ústavu, Brno
2 Oddělení gynekologické onkologie Kliniky operační onkologie, Lékařská fakulta Masarykovy univerzity, Brno
3 Gynekologicko-porodnické oddělení, Nemocnice Milosrdných bratří, Brno

Carcinoma of the uterine cervix is the most frequent malignant disease diagnosed in pregnant women. Most cases are early carcinomas due to cervical screening methods (PAPP smear, HPV DNA testation and colposcopy). However sometimes the results of the examination are unclear due to the physiological pregnancy associated changes of the cervical epithelium (squamous of the vaginal portion and columnar of the cervical canal). Cervical cancer complicating pregnancy is a specific clinical situation, that requires individual approach, multidisciplinary experienced team of specialists in gynaecological oncology and in obstetrics, respecting the opinion of the pregnant woman. Placenta accreta represents the most frequent type of abnormally adherent placenta, where placental villi are attached to the myometrium. Placenta accreta may be ultrasonically diagnosed antepartum. The main etiological factors are previous caesarean section scar (or other previous uterine incisions, uterine curettage) and older age of pregnant women.

Keywords: adenocarcinoma of the uterine cervix, pregnancy, obstetrical hemorrhage, life-threatening obstetrical hemorrhage, abnormally adherent placenta - placenta accreta.

Accepted: November 18, 2024; Published: November 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Velčický F, Náležinská M, Nagy J, Chovanec J. Incidental finding of cervical adenocarcinoma after complication of caesarean section. Onkologie. 2024;18(5):300-304. doi: 10.36290/xon.2024.062.
Download citation

References

  1. Pařízek A, Binder T, Bláha J, et al. Diagnostika a léčba peripartálního život ohrožujícího krvácení. Česká gynekologie. Praha: Česká lékařská společnost Jana Evangelisty Purkyně. 2018;83:151-158.
  2. Tunçalp Ö, Souza JP, Gülmezoglu M. New WHO recommendations on prevention and treatment of postpartum hemorrhage. International Journal of Gynecology & Obstetrics. 2013;123(3):254-256. Go to original source... Go to PubMed...
  3. Rob L, Martan A, Ventruba P, et al. Gynekologie. Praha: Galén; 2019.
  4. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [Internet]. Brno: Masarykova univerzita; 2005. [cit. 2024-8-02]. Available from: www: http://www.svod.cz. Verze 7.0 [2007].
  5. Halaška M, Rob L. Onkologická onemocněnî během těhotenstvî. Praha: Mladá fronta; 2015.
  6. Smith LH, Danielsen B, Allen ME, et al. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. American journal of obstetrics and gynekology. 2003;189(4):1128-1135. Go to original source... Go to PubMed...
  7. Duggan B, Muderspach LI, Roman LD, et al. Cervical cancer in pregnancy: reporting on planned delay in therapy. Obstet Gynecol. 1993;82(4 Pt 1):598-602. PMID: 8377988. Go to original source...
  8. Cibula D, Petruželka L, et al. Onkogynekologie. Praha: Grada; 2009.
  9. Chovanec J, Náležinská M. Přehled diagnostiky a léčby karcinomu děložního hrdla. Onkologie. 2014;8(6):269-274.
  10. Brůčková M. Nobelova cena za rok 2008 [Internet]. Zprávy epidemiologie a mikrobiologie, Praha: SZÚ. 2009;18(2):71-72. [cit. 2024-08-02]. Available from: http://www.szu.cz/publikace/zpravy-epidemiologie-amikrobiologie/zpravy-em-2-unor-2009.
  11. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecologic onkology. 2008;110(3):S4-S7. Go to original source... Go to PubMed...
  12. Sláma J, Dvořák V, Trnková M, et al. Význam doplnění cytologického screeningu karcinomu děložního hrdla o HPV DNA test a třídění nálezů imunocytochemickým barvením p16/Ki67 u žen ve věku 35 a 45 let. Analýza dat LIBUŠE. Česká gynekologie. Praha: Česká lékařská společnost Jana Evangelisty Purkyně. 2020;85(6):368-374.
  13. Sehnal B, Kmoníčková E, Sláma J, et al. Současný FIGO staging karcinomu děložního hrdla a léčba jednotlivých stadií. Klinická onkologie. 2019;32:3. Go to original source... Go to PubMed...
  14. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynecology & Obstetrics. 2009;105(2):103-104. Go to original source... Go to PubMed...
  15. Vercellino GF, Koehler C, Erdemoglu E, et al. Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer. 2014;24(2):364-371. doi: 10.1097/IGC.0000000000000064. PMID: 24424374. Go to original source... Go to PubMed...
  16. Amant F, Halaska MJ, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. International Journal of Gynecologic Cancer. 2014;24(3):394-403. Go to original source... Go to PubMed...
  17. Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2010;(1):CD007406. doi: 10.1002/14651858.CD007406.pub2. Update in: Cochrane Database Syst Rev. 2012;12:CD007406. doi: 10.1002/14651858.CD007406.pub3. PMID: 20091632. Go to original source... Go to PubMed...
  18. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. American journal of clinical onkology. 2010;33(3):221-228. Go to original source... Go to PubMed...
  19. Robova H, Halaska MJ, Pluta M, et al. Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecol Oncol. 2014;135(2):213-216. doi: 10.1016/j.ygyno.2014.08.021. Epub 2014 Aug 23. PMID: 25159484. Go to original source... Go to PubMed...
  20. Köhler C, Oppelt P, Favero G, et al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. Am J Obstet Gynecol. 2015;213(2):206.e1-5. doi: 10.1016/j.ajog.2015.02.022. Epub 2015 Feb 27. PMID: 25731691. Go to original source... Go to PubMed...
  21. Zemlickis D, Klein J, Moselhy G, et al. Cisplatin protein binding in pregnancy and the neonatal period. Med Pediatr Oncol. 1994;23(6):476-479. doi: 10.1002/mpo.2950230605. PMID: 7935173. Go to original source... Go to PubMed...
  22. Lee JM, Lee KB, Kim YT, et al. Cervical cancer associated with pregnancy: results of a multicenter retrospective Korean study (KGOG-1006). Am J Obstet Gynecol. 2008;198(1):92.e1-6. doi: 10.1016/j.ajog.2007.06.077. Epub 2007 Oct 1. PMID: 17905175. Go to original source... Go to PubMed...
  23. Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2015;373(19):1824-1834. doi: 10.1056/NEJMoa1508913. Epub 2015 Sep 28. PMID: 26415085. Go to original source... Go to PubMed...
  24. Goldman NA, Goldberg GL. Late recurrence of squamous cell cervical cancer in an episiotomy site after vaginal delivery. Obstetrics & Gynecology. 2003;101(5):1127-1129. Go to original source... Go to PubMed...
  25. Nocarová L, Ondruš D. Zhubné nádory krčka maternice v gravidite. Klinická onkologie. 2020;33(4):268-273. Go to original source... Go to PubMed...
  26. Doležal A, et al. Porodnické operace. Praha: Grada; 2007.
  27. Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019 [online], NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2019, 17.1. [cit. 2024-08-02]. Available from: https://jnccn.org/doi/10.6004/jnccn.2019.0001.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.